http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
전골수구백혈병 세포주 HL-60에 대한 Eugenol의 세포자멸사(Apoptosis) 유도 효과
길욱현,이기현,이경태,진종률 대한혈액학회 2005 Blood Research Vol.40 No.2
배경: Eugenol은 정향나무(Eugenia caryophyllata)로부터 분리된 정유의 주요 성분이며 주로 치과용 국소 마취, 진통제로 전통적으로 사용된다. 본 연구는 전골수구백혈병 세포주(human promyelocytic leukemia cells, HL-60)에서의 eugenol의 세포 독성 효과, apoptosis의 유도와 apoptosis에 관련되는 경로를 조사하였다. 방법: HL-60 세포에 eugenol을 처리하여 propididum 과 rhodamin 123 이중염색과 2',7'-dicholorofluore scindiacetate를 이용하여 반응 산소 물질(reactive oxygen species, ROS)과 미토콘드리아 막전압(mitocho drialmembrane potential, △Ψm)을 평가하였다. 결과: Eugenol은 apoptosis의 강력한 유도물질이고 반응 산소 물질의 생성을 통해 apoptosis 신호를 전달시켜 미토콘드리아 투과성 전이(mitochondrial permea bility transition, MPT)와 세포질 내로의 cytochrome c의 방출을 유도하였다. 반응 산소 물질의 생성, 미토콘드리아의 변화, 그에 따른 eugenol로 처리한 세포에서의 apoptotic cell death는 항산화제인 N-acetylcystein (NAC)에 의해서 차단되었다.
혈액투석을 위한 내경정맥 도관 삽입 중 발생한 상대 정맥 증후군
길욱현 ( Gil Ug Hyeon ),송호철 ( Song Ho Cheol ),백정선 ( Baeg Jeong Seon ),김진수 ( Kim Jin Su ),조근종 ( Jo Geun Jong ),이지인 ( Lee Ji In ),남유정 ( Nam Yu Jeong ),최의진 ( Choe Ui Jin ),장윤식 ( Jang Yun Sig ) 대한신장학회 2004 Kidney Research and Clinical Practice Vol.23 No.2
Most cases of superior vena cava (SVC) syndrome are secondary to malignant disease and subacute in their presentation. However, the exponential increase in use of indwelling central venous catheters and cardiac pacemakers over the last two decades has resulted in more patients with SVC syndrome. Internal jugular vein cannulation has become the preferred approach for temporary hemodialysis catheter placement following the reports of an increased in cidence of subclavian vein stenosis due to subclavian vein catheterization. We describe a patient who developed SVC syndrome after internal jugular vein catheterization. The patient had been swollen the left arm intermittently due to left central vein stenosis for 1 year and experienced balloon angioplasty and stent insertion for three times. We diagnosed the SVC syndrome through the both subclavian venography, which revealed complete obstruction of the left brachiocephalic vein with extensive collateral circulation and mild stenosis of the distal right internal jugular vein. Resolution of the clinical SVC sydrome occurred after catheter removal. (Korean J Nephrol 2004;23(2):349-352)
뇌하수체 거대종양에 동반된 부신피질자극호르몬 유리호르몬 결핍증 1예
남유정,김진수,조근종,길욱현,우성용,김성래,유순집,강성구,손호영 대한내분비학회 2006 Endocrinology and metabolism Vol.21 No.2
Pituitary tumor can be accompanied with various pituitary hormone abnormalities. Pituitary tumors can be divided into functioning or nonfunctioning tumors. A functioning pituitary tumor, via the oversecretion of pituitary hormones, causes diverse clinical features. A nonfunctioning pituitary tumor can be accompanied with pituitary dysfunction and this may be due to compression or destruction of normal pituitary tissue, suppression of the pituitary portal system or direct damage to the hypothalamus. Corticotropin-releasing hormone (CRH) deficiency, which is caused by defects in the synthesis or release of CRH, is a cause of secondary adrenocortical insufficiency. The clinical presentations are hypoglycemia, weight loss, anemia, weakness, nausea, vomiting and hyponatremia. Acquired CRH deficiency has also been suggested to occur based on a lack of adrenocorticotropic hormone (ACTH) response to insulin-induced hypoglycemia, but there is a normal ACTH response to exogenous CRH. We experienced a case of a woman with pituitary macroadenoma accompanied with CRH deficiency. We report here on this case with the review of the literature. (J Kor Soc Endocrinol 21:153~157, 2006) 저자들은 오심, 구토 및 어지러움증을 주소로 내원한 환자에서 복합뇌하수체 자극검사와 부신피질자극호르몬 유리호르몬 자극검사를 시행하여 뇌하수체 거대종양에 동반된 부신피질자극호르몬 유리호르몬 결핍증을 경험하였기에 문헌고찰과 함께 보고하는 바이다.
알파 인터페론 불응성 만성골수성백혈병 환자에서 Imatinib Mesylate 치료 후 골수섬유화의 반전 1예
김연성,김태훈,김원철,전연주,길욱현,이혜경,김영식,노상영,조석구 대한혈액학회 2005 Blood Research Vol.40 No.2
만성골수성백혈병 환자에서 골수섬유화는 불량한 예후와 관련이 있다. 골수섬유화는 초진 시에도 발견되지만 만성골수성백혈병의 형질전환 시에도 발견된다. 골수섬유화에 대한 알파 인터페론 요법의 효과는 논란의 여지가 있지만, imatinib mesylate 요법은 필라델피아 염색체-양성 세포의 조절은 물론 골수섬유화의 정도를 감소시키는 데도 효과적인 것으로 알려져 있다.
박훈준,승기배,김범준,박찬석,길욱현,백상홍,최규보 대한심장학회 2007 Korean Circulation Journal Vol.37 No.3
Deciding on the appropriate antiplatelet therapy is a challenge when treating patients with idiopathic thrombocytopenicpurpura (ITP) and who are undergoing percutaneous coronary intervention (PCI). We describe here acase of PCI in a patient with chronic, refractory ITP. A 61-year-old woman presented with exertional chest painand a low platelet count (4×109/L) at admission. Coronary angiography revealed 99% stenosis of the mid leftanterior descending artery and 95% stenosis of the mid left circumflex artery. Antiplatelet agents couldn’t beadministered because of the risk of bleeding. After transfusion of platelets and administering intravenous immunoglobulin,we deployed baremetal stents in both lesions without administering any antiplatelet agents. Althoughfocal in-stent restenosis developed 5 months later, there was no episode of stent thrombosis despite not usingantiplatelet agents. The present case suggests that the rate of stent thrombosis may be lower was previously thoughtand antiplatelet therapy may be considered on a case by case for patient suffering with thrombocytopenia.(Korean Circulation J 2007;37:87-90)